Citations

Clear

154 citation(s) found for "Levin, G".

LTBK-01. PHASE 3 STELLAR STUDY SHOWS EFLORNITHINE IMPROVES OVERALL SURVIVAL (OS) AND PROGRESSION FREE SURVIVAL (PFS) IN PATIENTS WITH RECURRENT 2021 WHO ASTROCYTOMA, IDH-MUTANT GRADE 3
Colman, Howard , Walbert, Tobias , Lassman, Andrew B. , Kizilbash, Sani H. , Kamiya-Matsuoka, Carlos, Pitz, Marshall , Desjardins, Annick , Kumthekar, Priya , Mason, Warren, Butowski, Nicholas , Forsyth, Peter, Hamza, Mohamed A. , Lallana, Enrico C., Uhlmann, Erik J. , Welsh, Liam , Wen, Patrick Y. , Dietrich, Jörg , Levin, Victor A. , Kizilbash, Sani H , Colman, Howard , Lombardi, Giuseppe , Wong, Eric T. , Eoli, Marica , Peereboom, David M. , Strowd, Roy E. , Pellerino, Alessia , Soffietti, Riccardo , Hau, Peter , Nabors, Burt , Piccioni, David Eric , Wen, Patrick Yung

Mayo Clinic

Neuro-Oncology | November 22, 2024 | Volume: 26 | Issue: Supplement_8 | Pages: viii1-viii1

10.1093/neuonc/noae165.1301 Get It

Abstract BACKGROUND Recurrent anaplastic astrocytoma (AA), a grade 3 brain cancer, remains an unmet medical need. STELLAR was a phase III randomized, open-label trial of eflornithine (ornithine decarboxylase inhibitor) with lomustine versus lomustine alone, originally for patients with recurrent AA. However, as the WHO definition of AA evolved during trial conduct (e.g., excluding IDH wild-type disease), we determined results in both the original ITT population and by revised molecularly defined WHO 2021 diagnoses in pre-planned analyses. METHOD Key eligibility: age ≥ 18, AA (2016 WHO criteria), first recurrence ≥ 6 months after radiation and temozolomide, KPS ≥ 70, no imaging findings consistent with grade 4 glioblastoma. Stratification: IDH, age, resection extent, and geography. Patients were randomized to Arm A: eflornithine (2.8 g/m2 TID Q 2/3 weeks) with lomustine (90 mg/m2 Q 6 weeks) or Arm B: lomustine (110 mg/m2 Q 6 weeks). Primary endpoint was OS. The pre-specified hazard ratio (HR) goal was 0.667 based on projected median OS (mOS) increase to 18 months from 12 months. RESULTS 343 pts (172/171 Arms A/B) were randomized (105 sites, 8 countries). ITT analysis found no difference between arms (mOS 23.4 vs. 20.3 months, HR = 0.94). However, a pre-specified subset analysis in IDH mutant, 2021 WHO-defined grade 3 astrocytoma (n=194), showed significant improvement with eflornithine (mOS 34.9 vs. 23.5 months, HR = 0.64, log rank p = 0.016) and PFS (15.8 vs. 7.2 months, HR = 0.58, log rank p = 0.015). No difference was observed in the IDH wild-type subset. AEs were consistent with historic data. CONCLUSION There was no difference in OS between arms in the ITT analysis. However, medically meaningful and statistically significant OS and PFS benefits were observed with eflornithine in the pre-planned analysis of patients with molecularly defined 2021 WHO CNS grade 3 astrocytoma.
Abstract B022: Precision medicine for the fusion protein driven cancer, fibrolamellar carcinoma (FLC): Beyond sequencing
Shirani, Mahsa , Requena, David , Ng, Denise , Molina, Henrik , Rice, Charles M. , Lyons, Barbara A. , Requena, David , Simon, Sanford M. , Lalazar, Gadi , Levin, Solomon , Torbenson, Michael , Singhi, Aatur Dilip , Coffino, Philip

Mayo Clinic

Cancer Research | September 5, 2024 | Volume: 84 | Issue: 17_Supplement | Pages: B022-B022

10.1158/1538-7445.pediatric24-b022 Get It

Abstract Fibrolamellar carcinoma (FLC) is a rare, usually lethal primary liver tumor that affects children, adolescents and young adults. Sequencing of FLC tumors in hepatocytes reveals that in 99% of the patients there is one recurrent genomic alteration: A deletion of 400 kB. This produces DNAJB1::PRKACA, a fusion of the first exon of DNAJB1 with the 2nd – 10th exons of PRKACA, the catalytic subunit of protein kinase A (PKA). PKA exists as a holoenzyme of two catalytic subunits and two regulatory subunits. The regulatory subunit both inhibits the catalytic and localizes it in the cell. Calibrated mass spectrometry shows that in normal liver there is always an excess of regulatory>catalytic subunits, but in the adjacent FLC tumor tissue there is an excess of catalytic>regulatory subunits. Different biochemistry assays and proximity ligation reveal both free catalytic, unbound to regulatory subunits, and an increase of kinase activity in the tumor cells. Much of the increase of catalytic subunit is in the nucleus. Transducing primary human hepatocytes (PHH) with DNAJB1::PRKACA is sufficient to recapitulate the transcriptome of FLC tumors. Transduction of PHH with just the wt PRKACA is also sufficient to recapitulate the transcriptome of FLC tumors. Thus, just increasing the level of kinase is sufficient, there is nothing special about the fusion domain. From our tissue repository we have four patients who have a tumor that looks like FLC but does not have a fusion to the catalytic subunit. The only alteration in these patients is loss of regulatory subunit. The transcriptome of these patient tumors is indistinguishable from that of classic DNAJB1::PRKACA FLC in hepatocytes. Additionally, we have a few dozen patients who have either DNAJB1::PRKACA or another fusion, ATP1B1::PRKACA in the ductal cells of their liver (producing cholangiocarcinomas) or ductal cells of their pancreas (producing IOPN, Intraductal Oncolytic Pancreatic Neoplasms). The transcriptome of these patients clusters with the transcriptome of the FLC patients with DNAJB1::PRKACA in the hepatocytes. A functional precision medicine drug repurposing screen found that the EC50 of the response of freshly resected tumors from patients to a wide panel of drugs is the same as that of FLC patients with DNAJB1::PRKACA in their hepatocytes. Based on sequencing one could conclude that patients with deletion of regulatory subunit in the hepatocytes, or expression of DNAJB1::PRKACA in the hepatocytes, or expression of DNAJB1::PRKACA or ATP1B1::PRKACA in the cholangiocytes or pancreatic ductal cells are at least three distinct diseases. An analysis of the cell biological changes reveals that they all of an increase of the ratio of catalytic:regulatory subunit, they have an increase of catalytic subunit in the nucleus, and these all result in the same changes of transcriptome and the same drug-response profile. Thus, looking beyond sequencing to the cellular changes leads to a different conclusion, that maybe they should be considered the same disease. Citation Format: Sanford Simon, Mahsa Shirani, David Requena, Denise Ng, Gadi Lalazar, Solomon Levin, Michael S. Torbenson, Aatur D. Singhi, Henrik Molina, Charles M. Rice, Philip Coffino, Barbara A. Lyons. Precision medicine for the fusion protein driven cancer, fibrolamellar carcinoma (FLC): Beyond sequencing [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Pediatric Cancer Research; 2024 Sep 5-8; Toronto, Ontario, Canada. Philadelphia (PA): AACR; Cancer Res 2024;84(17 Suppl):Abstract nr B022.
Application of the international criteria for optic neuritis in the Acute Optic Neuritis Network
Klyscz, Philipp , Asseyer, Susanna , Bereuter, Charlotte , Bialer, Omer , Bick, Atira, Carta, Sara , Chen, John J. , Cohen, Leila , Cohen‐Tayar, Yamit , Gernert, Jonathan A. , Haas, Julian , Heesen, Christoph , Hellmann, Mark A. , Levin, Netta , Lotan, Itay , Luis, María Belén , Vergara, Alvaro Jose Mejia, Ocampo, Cassandra, Ochoa, Susana, Oertel, Frederike Cosima , Olszewska, Maja, Uribe, José Luis Peralta , Scocco, Darío H. , Shifa, Jemal Zeberga, Simantov, Ilya, Tiosano, Alon , Torres-Camacho, Isabel , Dembinsky, Adi Vaknin, Vidal‐Jordana, Ángela , Wilf‐Yarkoni, Adi , Wu, Ti , Zamir, Sol, Zarco, Luis Alfonso , Zimmermann, Hanna , Paul, Friedemann , Dale, Russell C , Levin, Netta , Lotan, Itay , Mariotto, Sara , Oertel, Frederike C , Sastre-Garriga, Jaume , Ramanathan, Sudarshini , Rattanathamsakul, Natthapon , Shi, Fu-Dong , Tisavipat, Nanthaya , Zimmermann, Hanna G , Paul, Friedemann , Chen, John J , Carta, Sara , Alonso, Ricardo Nicolás , Contentti, Edgar Carnero , Dale, Russell C. , Flanagan, Eoin P. , Haas, Julian, Havla, Joachim , López, Pablo A. , Mariotto, Sara , Mayer, Christina , Mejía-Vergara, Álvaro J. , Ramanathan, Sudarshini , Rattanathamsakul, Natthapon , Siritho, Sasitorn , Tisavipat, Nanthaya , Petzold, Axel , Stiebel‐Kalish, Hadas

Mayo Clinic

Annals of Clinical and Translational Neurology | August 5, 2024 | Volume: 11 | Issue: 9 | Pages: 2473-2484

10.1002/acn3.52166 | PMID 39099240 Get It

AbstractObjectiveThe first international consensus criteria for optic neuritis (ICON) were published in 2022. We applied these criteria to a prospective, global observational study of acute optic neuritis (ON).MethodsWe included 160 patients with a first‐ever acute ON suggestive of a demyelinating CNS disease from the Acute Optic Neuritis Network (ACON). We applied the 2022 ICON to all participants and subsequently adjusted the ICON by replacing a missing relative afferent pupillary defect (RAPD) or dyschromatopsia if magnetic resonance imaging pathology of the optical nerve plus optical coherence tomography abnormalities or certain biomarkers are present.ResultsAccording to the 2022 ICON, 80 (50%) patients were classified as definite ON, 12 (7%) patients were classified as possible ON, and 68 (43%) as not ON (NON). The main reasons for classification as NON were absent RAPD (52 patients, 76%) or dyschromatopsia (49 patients, 72%). Distribution of underlying ON etiologies was as follows: 78 (49%) patients had a single isolated ON, 41 (26%) patients were diagnosed with multiple sclerosis, 25 (16%) patients with myelin oligodendrocyte glycoprotein antibody‐associated disease, and 15 (9%) with neuromyelitis optica spectrum disorder. The application of the adjusted ON criteria yielded a higher proportion of patients classified as ON (126 patients, 79%).InterpretationAccording to the 2022 ICON, almost half of the included patients in ACON did not fulfill the requirements for classification of definite or possible ON, particularly due to missing RAPD and dyschromatopsia. Thorough RAPD examination and formal color vision testing are critical to the application of the 2022 ICON.
Fecal Immunochemical Test Screening and Risk of Colorectal Cancer Death
Corley, Douglas A. , Levin, Theodore R. , Ghai, Nirupa R. , Zhao, Wei , Buckner‐Petty, Skye , Fletcher, Robert H., Schottinger, Joanne E. , Buckner-Petty, Skye, Doubeni, Chyke A. , Jensen, Christopher D. , Cannavale, Kimberly L. , Selby, Kevin , Zauber, Ann Graham , Weiss, Noel S

Mayo Clinic

JAMA Network Open | July 19, 2024 | Volume: 7 | Issue: 7 | Pages: e2423671

10.1001/jamanetworkopen.2024.23671 | PMID 39028667 Get It

ImportanceThe fecal immunochemical test (FIT) is widely used for colorectal cancer (CRC) screening, but evidence of its effectiveness is limited.ObjectiveTo evaluate whether FIT screening is associated with a lower risk of dying from CRC overall, according to cancer location, and within demographic groups.Design, Setting, and ParticipantsThis nested case-control study in a cohort of screening-eligible people was conducted in 2 large, integrated health systems of racially, ethnically, and socioeconomically diverse members with long-term programs of mailed FIT screening outreach. Eligible participants included people aged 52 to 85 years who died from colorectal adenocarcinoma between 2011 and 2017 (cases); cases were matched in a 1:8 ratio based on age, sex, health-plan membership duration, and geographic area to randomly selected persons who were alive and CRC-free on case’s diagnosis date (controls). Data analysis was conducted from January 2002 to December 2017.ExposuresCompleting 1 or more FIT screenings in the 5-year period prior to the CRC diagnosis date among cases or the corresponding date among controls; in secondary analyses, 2- to 10-year intervals were evaluated.Main Outcomes and MeasuresThe primary study outcome was CRC death overall and by tumor location. Secondary analyses were performed to assess CRC death by race and ethnicity.ResultsFrom a cohort of 2 127 128 people, a total of 10 711 participants (3529 aged 60-69 years [32.9%]; 5587 male [52.1%] and 5124 female [47.8%]; 1254 non-Hispanic Asian [11.7%]; 973 non-Hispanic Black [9.1%]; 1929 Hispanic or Latino [18.0%]; 6345 non-Hispanic White [59.2%]) was identified, including 1103 cases and 9608 controls. Among controls during the 10-year period prior to the reference date, 6101 (63.5%) completed 1 or more FITs with a cumulative 12.6% positivity rate (768 controls), of whom 610 (79.4%) had a colonoscopy within 1 year. During the 5-year period, 494 cases (44.8%) and 5345 controls (55.6%) completed 1 or more FITs. In regression analysis, completing 1 or more FIT screening was associated with a 33% lower risk of death from CRC (adjusted odds ratio [aOR], 0.67; 95% CI, 0.59-0.76) and 42% lower risk in the left colon and rectum (aOR, 0.58; 95% CI, 0.48-0.71). There was no association with right colon cancers (aOR, 0.83; 95% CI, 0.69-1.01) but the difference in the estimates between the right colon and left colon or rectum was statistically significant (P = .01). FIT screening was associated with lower CRC mortality risk among non-Hispanic Asian (aOR, 0.37; 95% CI, 0.23-0.59), non-Hispanic Black (aOR, 0.58; 95% CI, 0.39-0.85) and non-Hispanic White individuals (aOR, 0.70; 95% CI, 0.57-0.86) (P for homogeneity = .04 for homogeneity).Conclusions and RelevanceIn this nested case-control study, completing FIT was associated with a lower risk of overall death from CRC, particularly in the left colon, and the associations were observed across racial and ethnic groups. These findings support the use of FIT in population-based screening strategies.
Increased Protein Kinase A Activity Induces Fibrolamellar Hepatocellular Carcinoma Features Independent of DNAJB1
Shirani, Mahsa , Levin, Solomon , Shebl, Bassem , Requena, David , Finkelstein, Tova M. , Johnson, Daniel S. , Ng, Denise , Heissel, Søren , Højrup, Peter , Molina, Henrik , Rice, Charles M. , Lyons, Barbara A. , Simon, Sanford M. , Lalazar, Gadi , Heissel, Søren , Hojrup, Peter , Molina, Henrik , de Jong, Ype P , Rice, Charles M , Singhi, Aatur Dilip , Torbenson, Michael S , Coffino, Philip , Lyons, Barbara , Simon, Sanford M , Requena, David , Levin, Solomon N , Jong, Ype P. de , Torbenson, Michael

Mayo Clinic

Cancer Research | June 18, 2024 | Volume: 84 | Issue: 16 | Pages: 2626-2644

10.1158/0008-5472.can-23-4110 | PMID 38888469 Get It

Abstract Fibrolamellar hepatocellular carcinoma (FLC) is a rare liver cancer that is driven by the fusion of DNAJB1 and PRKACA, the catalytic subunit of protein kinase A (PKA). PKA activity is controlled through regulatory proteins that both inhibit catalytic activity and control localization, and an excess of regulatory subunits ensures PRKACA activity is inhibited. Here, we found an increase in the ratio of catalytic to regulatory units in FLC patient tumors driven by DNAJB1::PRKACA using mass spectrometry, biochemistry, and immunofluorescence, with increased nuclear localization of the kinase. Overexpression of DNAJB1::PRKACA, ATP1B1::PRKACA, or PRKACA, but not catalytically inactive kinase, caused similar transcriptomic changes in primary human hepatocytes, recapitulating the changes observed in FLC. Consistently, tumors in patients missing a regulatory subunit or harboring an ATP1B1::PRKACA fusion were indistinguishable from FLC based on the histopathological, transcriptomic, and drug–response profiles. Together, these findings indicate that the DNAJB1 domain of DNAJB1::PRKACA is not required for FLC. Instead, changes in PKA activity and localization determine the FLC phenotype. Significance: Alterations leading to unconstrained protein kinase A signaling, regardless of the presence or absence of PRKACA fusions, drive the phenotypes of fibrolamellar hepatocellular carcinoma, reshaping understanding of the pathogenesis of this rare liver cancer.
A phase 2 randomized trial of neoadjuvant enoblituzumab versus standard of care in men with high-risk localized prostate cancer: The help elucidate and attack longitudinally (HEAT) prostate cancer randomized study.
Wang, Hao , Shah, Paras , Yang, Ximing J. , Murugan, Paari , Gupta, Sounak , Warlick, Christopher A. , Boorjian, Stephen A. , Ross, Ashley E. , Shenderov, Eugene , Marzo, Angelo M. De , Lotan, Tamara Levin , Schaeffer, Edward M. , Hussain, Maha , Sartor, Oliver , Pavlovich, Christian P. , Antonarakis, Emmanuel S. , Allaf, Mohamad E

Mayo Clinic

Journal of Clinical Oncology | June 6, 2024 | Volume: 42 | Issue: 16_suppl | Pages: TPS5125-TPS5125

10.1200/jco.2024.42.16_suppl.tps5125 Get It

TPS5125 Background: B7-H3 is a member of the B7 superfamily, which includes PD-L1 (B7-H1) and PD-L2 (B7-DC). Enoblituzumab is a humanized Fc-optimized B7-H3–targeting antibody that induces antibody-dependent cellular cytotoxicity (ADCC). A recent investigator-initiated trial demonstrated that enoblituzumab therapy, used in the neoadjuvant prostate cancer setting, is feasible, safe, may enhance short-term clinical outcomes, and appears to stimulate intratumoral immune activation including CD8+ T cell infiltration and peripheral expansion of tumor-infiltrating T-cell clones that correlated with undetectable PSA at 1-year post-prostatectomy. To assess the impact of enoblituzumab on recurrence-free survival following prostatectomy, a phase 2, randomized, neoadjuvant clinical trial in high-risk localized prostate cancer patients has been started. We hypothesize that targeting B7-H3 with enoblituzumab will delay or prevent recurrence following prostatectomy compared to standard of care (SOC) . Methods: The HEAT trial is an investigator-initiated, multi-center, randomized, phase 2 study that is presently enrolling (NCT06014255). Eligible patients will undergo a pre-treatment prostate biopsy and conventional imaging (CT and bone scan) as well as PSMA-PET. Patients who have clinical stage cT1c-T3b, cN0 cM0 disease by conventional imaging (N1 by PSMA allowed with up to 3 LNs each ≤1 cm) will be eligible as long as concurrent hormonal or radiation therapy is not given. Prostate biopsy, within 3 months of enrollment, needs to show at least 3 positive cores containing at least 1 core with at least 50% disease involvement with Gleason ≥4+3=7 disease (with at least 1 additional high-risk feature such as PSA>20 ng/ml or cT3) or a Gleason sum ≥8. Patients will receive enoblituzumab at a dose of 15mg/kg IV biweekly for 6 doses (12 weeks) on the treatment arm, followed by prostatectomy, or will be scheduled for prostatectomy directly within 4-8 weeks on the SOC arm. 219 patients will be randomized (2:1) to treatment versus SOC. Pre-treatment, on-treatment, and post-treatment biomarkers of response and resistance will be collected. Patients will be followed according to standard institutional practices, but will require PSA evaluations every 3 (±1) months during year 1 and every 6 (±2) months during years 2-5. In both arms, salvage or adjuvant therapy will occur after biochemical or radiographic progression. The primary endpoint is recurrence-free survival (RFS) defined as any metastasis events, local pelvic visceral or lymph node recurrence, detectable prostate-specific antigen (PSA), or start of subsequent local or systemic therapy (including salvage or adjuvant therapy), or death for any cause, whichever occurs first. Secondary endpoints include additional clinical and immunologic correlates. Clinical trial information: NCT06014255 .
1152 A Journey Through Kleine-Levin Syndrome: A Longitudinal Case Report
Tu, Xinhang , Lipford, Melissa C.

Mayo Clinic

SLEEP | April 20, 2024 | Volume: 47 | Issue: Supplement_1 | Pages: A493-A494

10.1093/sleep/zsae067.01152 Get It

Abstract Introduction Kleine-Levin Syndrome (KLS) is a rare disease with intermittent episodes of hypersomnia with behavioral abnormalities. We present a case of KLS with successful symptomatic treatment with modafinil and eventual remission. Report of case(s) A 19-year-old healthy male with no prior sleep disorders was referred for evaluation of hypersomnia. He developed leg cellulitis requiring antibiotic therapy. Shortly afterwards, he developed abnormal behaviors --quitting school, estrangement from friends, sleeping 20 hours a day, irritability, and suppressed appetite. He also demonstrated hypersexuality and disinhibited behaviors. After 10 days, he abruptly returned to baseline and had limited recall of the prior events. Three months later, he had a second episode with similar behavioral and sleep changes, again followed by spontaneous return to baseline after 10 days. Two months later, a similar spell occurred, prompting arrangement for psychiatric admission and initiation of quetiapine for a proposed diagnosis of rapid-cycling bipolar disorder. His symptoms again resolved spontaneously. Diagnostic tests including liver function tests, thyroid function tests, ammonia level, urine drug screen, Lyme disease, MRI brain, EEG, and CSF analysis were unremarkable. He was eventually referred to the Sleep Medicine clinic for evaluation. There were no symptoms suggesting other comorbid sleep disorders, and he had a normal neurologic and physical exam at time of presentation. A clinical diagnosis of KLS was made. The patient and family deferred prophylactic or abortive treatment (such as lithium, carbamazepine, or steroids) due to potential for side effects. Modafinil provided symptomatic benefits during the three milder episodes he had over the next few years. Episodes subsequently resolved and the patient is currently in remission (over 5 years) without sequalae. Conclusion KLS is a rare disease with typical onset during young adulthood, manifesting with abrupt onset of recurrent episodes of hypersomnia and prolonged sleep duration, lasting from days to several weeks. The diagnosis is clinical and requires at least one additional feature including: cognitive dysfunction, derealization, major apathy, or disinhibited behaviors. Patients revert to baseline between the episodes. Stimulants such as modafinil can promote wakefulness during the episodes. Support (if any) N/A
Prostate Cancer, Version 3.2024
Schaeffer, Edward M. , Srinivas, Sandy, An, Yi , Bitting, Rhonda L. , Chapin, Brian F. , D’Amico, Anthony V. , Desai, Neil , Dorff, Tanya B. , Eastham, James A., Farrington, Thomas A., Gupta, Shilpa , Guzzo, Thomas, Karnes, R. Jeffrey , Kuettel, Michael, McKay, Rana R. , Morgan, Todd M. , Pow‐Sang, Julio M. , Reiter, Robert E. , Roach, Mack , Rosenfeld, Stan, Shabsigh, Ahmad , Valicenti, Richard K., Wong, J.K. , Snedeker, Jenna, Freedman-Cass, Deborah A., Morgan, Todd M , Robin, Tyler P. , Adra, Nabil , Cheng, Heather H. , Gao, Xin Yuan , Ippolito, Joseph E. , Lang, Joshua M. , Lotan, Tamara Levin , Spratt, Daniel E. , Szmulewitz, Russell Z , Teply, Benjamin A. , Tward, Jonathan D.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | April 16, 2024 | Volume: 22 | Issue: 3 | Pages: 140-150

10.6004/jnccn.2024.0019 | PMID 38626801 Get It

The NCCN Guidelines for Prostate Cancer include recommendations for staging and risk assessment after a prostate cancer diagnosis and for the care of patients with localized, regional, recurrent, and metastatic disease. These NCCN Guidelines Insights summarize the panel's discussions for the 2024 update to the guidelines with regard to initial risk stratification, initial management of very-low-risk disease, and the treatment of nonmetastatic recurrence.
Rituximab or cyclosporine A for the treatment of membranous nephropathy: economic evaluation of the MENTOR trial
So, Helen , Fervenza, Fernando C. , Cattran, Daniel C., Barbour, Sean J. , Investigators, MENTOR Study, Cattran, D C, Appel, Gerald B., Gipson, D, Erickson, Stephen B., Radhakrishnan, Jay, Bomback, A.S., Hogan, Jonathan, Arora, Neha , Nargund, Preeti, Alvarado, Anthony, Hebert, Lee A., Aslam, Nabeel , Porter, Ivan E. , Gipson, Patrick E., Plattner, Brandon L. , Gipson, D, Mariani, Laura , Garg, Pranay, Jefferson, J. Ashley , Nelson, Peter J. , Yarlagadda, Sri G. , Simon, James F. , Gebreselassie, Surafel , Blumenthal, Stanley A., Thomas, L, Cohen, Irvin M., Keddis, Mira T. , Sussman, Andrew L. , Thajudeen, Bijin , Fülöp, Tibor , Craici, Iasmina , Wagner, Steven J., DREISBACH, A, Monga, D., Green, D, Nayer, Ali, Thomas, D. B., Cattran, D C, Reich, Heather N. , Barbour, S. Lee , Philibert, D., Mac‐Way, Fabrice , Desmeules, Simon, Ankawi, Ghada , Sethi, Sanjeev , Ávila-Casado, Carmen , Beanlands, Heather , Fervenza, Fernando C , Kadatz, Matthew , Klarenbach, Scott W , Investigators, MENTOR Study, Cattran, D C, Gipson, D, Kretzler, Matthias , Rovin, Brad H. , Lieske, John C. , Leung, Nelson , Canetta, Pietro A. , Ahn, W, Lafayette, Richard , Arora, N, Parikh, Samir M. , Plattner, B, Gipson, D, Rao, P, Sedor, John R. , O'Toole, J, McCarthy, E, Jain, Namrata Gargee , Rizk, D, Blumenthal, S, Beara‐Lasić, Lada , Zhdanova, Olga A. , Thomas, L, Sussman, A, Juncos, Luis A. , Fulop, T, Monga, D, Mattiazzi, Adela D. , Thomas, D, Barisoni, Laura , Li, T, Vijayan, Anitha , Cattran, D C, Hladunewich, Michelle , Barbour, S, Levin, Adeera , Philibert, D

Mayo Clinic

Nephrology Dialysis Transplantation | April 13, 2024 | Volume: 39 | Issue: 12 | Pages: 2058-2066

10.1093/ndt/gfae084 | PMID 38621719 Get It

ABSTRACT Background and hypothesis The MENTOR trial (MEmbranous Nephropathy Trial Of Rituximab) showed that rituximab was noninferior to cyclosporine in inducing complete or partial remission of proteinuria and was superior in maintaining proteinuria remission. However, the cost of rituximab may prohibit first-line use for some patients and health-care payers. Methods A Markov model was used to determine the incremental cost-effectiveness ratio (ICER) of rituximab compared with cyclosporine for the treatment membranous nephropathy from the perspective of a health-care payer with a lifetime time horizon. The model was informed by data from the MENTOR trial where possible; additional parameters including cost and utility inputs were obtained from the literature. Sensitivity analyses were performed to evaluate the impact of reduced-cost biosimilar rituximab. Results Rituximab for the treatment of membranous nephropathy was cost effective (assuming a willingness-to-pay threshold of $50 000 per quality-adjusted life year (QALY) gained; in $US 2021) compared with cyclosporine, with an ICER of $8373/QALY over a lifetime time horizon. The incremental cost of rituximab therapy was $28 007 with an additional 3.34 QALYs compared with cyclosporine. Lower cost of rituximab biosimilars resulted in a more favorable ICER, and in some cases resulted in rituximab being dominant (lower cost and great benefit) compared to cyclosporine. Conclusions Despite the greater cost of rituximab, it may be a cost-effective option for the treatment of membranous nephropathy when compared with cyclosporine. The cost-effectiveness of rituximab is further improved with the use of less expensive biosimilars.